百济神州2025年营收同比增长40.4%

Core Viewpoint - BeiGene reported a significant turnaround in its financial performance for the year 2025, achieving a total revenue of 38.205 billion yuan, a year-on-year increase of 40.4%, and a net profit attributable to shareholders of 1.422 billion yuan, compared to a net loss of 4.978 billion yuan in the previous year [1] Financial Performance - The total revenue for 2025 reached 38.205 billion yuan, marking a 40.4% increase compared to the previous year [1] - The net profit attributable to the parent company's shareholders was 1.422 billion yuan, a significant recovery from a net loss of 4.978 billion yuan in the prior year [1] - The increase in revenue was primarily driven by sales growth of Baiyueze®, licensed products from Amgen, and Baizean® [1] Operational Efficiency - The company achieved profitability in operating profit, total profit, net profit attributable to shareholders, net profit excluding non-recurring items, and basic earnings per share compared to the previous year [1] - The improvement in profitability was attributed to revenue growth from products and enhanced operational efficiency driven by effective cost management [1]